In conclusion, TYMS overexpression correlated with response to pemetrexed and death, and a significant benefit was observed in patients with low TYMS expression, suggesting that this enzyme might be used as a predictive biomarker in advanced NSCLC patients. Here, TYMS is linked to non-small cell lung carcinoma.